Fujisawa Pharmaceutical Company, Ltd.

Eiko Iguchi

Hiroshi Imanaka

Hatsuo Aoki

Masanobu Kohsaka

Hirokazu Tanaka

Yoshio Kuroda

Masashi Hashimoto

Keiji Hemmi

Satoshi Okada

Matsuhiko Aratani

Osamu Nakaguchi

Yoshihiko Kitaura

Hidekazu Takeno

Masakuni Okuhara

Michio Yamashita

Masanori Okamoto

Tadaaki Komori

Keizo Yoshida

Takeno Hidekazu

The invention relates to novel peptides, of pharmacological activity, of the formula: ##STR1## wherein R.sup.1 is hydrogen,

Peptide, process for preparation thereof and use thereof

The invention relates to novel peptides of enhanced pharmacological activity of the formula: ##STR1## wherein R.sup.1 is hydroxyalkanoyl,

The invention concerns peptides, having the pharmaceutical property of enhancing the immune response, having the structure: ##STR1## wherein R.sup.1 is alkanoyl,

The invention relates to novel peptides of enhanced pharmacological activity of the formula: ##STR1## wherein R.sup.1 is alkanoyl;

The invention relates to compounds and salts of compounds which are diaminopimelyl peptides, N-acetoxypropionyl or N-t-butoxycarbonyl-amino-acid - (.alpha.-OBzl) glutamic acid peptides or N-acylated derivatives of (.alpha.-OBzl) glytamic acid or of (.alpha.-OBzl) aminoadipic acid. The compounds and their salts are starting materials for the preparation of pharmacologically active peptides.

New peptide, process for preparation thereof and use thereof

The invention relates to a biologically pure culture of new strains of the microorganism Streptomyces which are capable upon fermentation of producing a peptide of pharmacological activity.

Cultures of novel strains of Streptomyces

The invention relates to novel intermediates for the preparation of peptides of pharmacological activity, said intermediates being of the formulas: ##STR1## wherein R.sub.2.sup.r is amino protective group and

Oxazole derivatives

Prodn. of FR-900129 comprises culturing a Streptomyces n. 4012 category which is analogous to Streptomyces misakiensis and Steptomyces aburaviensis, i.e. Streptomyces avellaneus No. 4012, at 25.degree. C. to 30.degree. C. during 50 to 100 hours in a culture medium which consists of a carbon source (e.g. glucose, fructose, glycerin, starch, galactose, maltose, dextrin), an organic or inorganic nitrogen source (e.g. yeast extract, peptone, cottonseed cake, soyabean powder, cornsteep liquor, dry yeast, ammonium nitrate, ammonium sulphate, ammonium phosphate, urea and amino acid) and an inorganic salt (e.g. calcium carbonate, sodium phosphate, potassium phosphate, sodium chloride, potassium chloride, magnesium salt and copper salt). The produced FR-900129 is isolated by a collecting step, a purifying step, a vacuum condensation step, a freeze-drying step, a pH adjusting step, a cationic, anionic or nonionic resin treating step, an active carbon adsorption step and a crystallizing and recrystallizing step. The isolated material may then be converted to its adduct salt or its ester conventionally.

Antibiotic FR-900129 substance, a process for the preparation thereof

The invention deals with novel peptides useful for the therapeutic treatment of infectious diseases caused by pathogenic microorganisms. Included is the peptide FR900156 having the structure: ##STR1## as well as the peptides of the structure ##STR2## wherein R.sup.1 is acyl;

Alkyl, alkenyl, and aryl substituted triazene compounds, their salts and

An antibiotic FR-900098 which has been assigned the chemical structure ##STR1## and another antibiotic FR-33289 which has been assigned the chemical structure ##STR2## have been isolated from cultured broths.

Growing community of inventors

Osaka, Japan

Eiko Iguchi